

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 03-465-C (400/142)	Serial No. 10/757,803
	Applicant: McSwiggen et al.	
	Filing Date: January 14, 2004	Group: 1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2003/0190635	07/25/02	McSwiggen et al.			10/09/03
	*	US-2003/206887	09/16/02	Morrissey			11/06/03
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,998,148	12/07/99	Bennett et al.			
	*	5,998,206	12/07/99	Cowser			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,346,398	02/12/02	Pavco et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwick et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 03-465-C (400/142)	Serial No. 10/757,803
	Applicant: McSwiggen et al.	
	Filing Date: January 14, 2004	Group: 1635

	*	7,078,196	07/18/06	Tuschl et al.			
--	---	-----------	----------	---------------	--	--	--

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
	1.	08208687	08/13/96	JP (Hotoda et al.) ABSTRACT ONLY				
	2.	03/044188	11/21/02	WO (Tei et al.)				
	3.	03/70918	08/23/03	WO (McSwiggen et al.)				
	4.	04/048566	11/21/03	WO (Saigo et al.)				
	5.	05/028650	03/31/05	WO (Jadhav et al.)				
	6.	05/049821	11/18/04	WO (Naito et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	7.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
	8.	Allerson et al., "Fully 2'-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA," <i>J. Med. Chem.</i> , 38:901-904 (2005)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-C (400/142)	Serial No. 10/757,803
		Applicant: McSwiggen et al.	
		Filing Date: January 14, 2004	Group: 1635

9.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
10.	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
11.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (11 pgs) (2001)
12.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
13.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
14.	Caplen, Natasha J., "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> , 3(4):575-586 (2003)
15.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
16.	Czauderna et al., "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells," <i>Nucleic Acids Research</i> , 31(11):2705-2716 (2003)
17.	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
18.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
19.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
20.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
21.	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
22.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-C (400/142)	Serial No. 10/757,803
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: January 14, 2004	Group: 1635

23.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
24.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
25.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
26.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
27.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
28.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
29.	Prakash et al., "Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells," <i>J. Med. Chem.</i> , 48, 4247-4253 (2005)
30.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
31.	Semizarov et al., "siRNA-mediated gene silencing: a global genome view," <i>Nucleic Acids Research</i> , 32(13):3836-3845 (2004)
32.	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
33.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
34.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)
35.	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <i>Cell</i> , 118:57-68 (2004)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.